Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo’s Enhertu met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pretreated patients, AstraZeneca announced. Enhertu is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. The DESTINY-PanTumor02 Phase II trial is evaluating the efficacy and safety of Enhertu in patients with locally advanced, unresectable, or metastatic previously treated, HER2-expressing solid tumours not eligible for curative therapy, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare cancers. The primary endpoint of the trial is investigator-assessed confirmed ORR and investigator-assessed duration of response, or DoR, is a key secondary endpoint. The data will be presented at an upcoming medical meeting and shared with global regulatory authorities. Reference Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca says FDA to convene AdCom meeting on sNDA for Lynparza in mCRPC
- Prenetics announces formation of scientific advisory board
- AstraZeneca completes acquisition of CinCor Pharma
- AstraZeneca reports Enhertu approved in China for metastatic breast cancer
- AstraZeneca announces license agreement with KYM Biosciences for CMG901